Search Results - "LaRosa, John C"

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population by Kaasenbrood, Lotte, Boekholdt, S Matthijs, van der Graaf, Yolanda, Ray, Kausik K, Peters, Ron J.G, Kastelein, John J.P, Amarenco, Pierre, LaRosa, John C, Cramer, Maarten J.M, Westerink, Jan, Kappelle, L Jaap, de Borst, Gert J, Visseren, Frank L.J

“…BACKGROUND:Among patients with clinically manifest vascular disease, the risk of recurrent vascular events is likely to vary. We assessed the distribution of…”
Get full text

Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers by Arsenault, Benoit J, Barter, Philip, DeMicco, David A, Bao, Weihang, Preston, Gregory M, LaRosa, John C, Grundy, Scott M, Deedwania, Prakash, Greten, Heiner, Wenger, Nanette K, Shepherd, James, Waters, David D, Kastelein, John J P

“…Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the…”
Get full text

Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (From the Treating to New Targets [TNT] Study) by Shepherd, James, MD, Breazna, Andrei, PhD, Deedwania, Prakash C., MD, LaRosa, John C., MD, Wenger, Nanette K., MD, Messig, Michael, PhD, Wilson, Daniel J., MD

“…Abstract Statins may have nephroprotective as well as cardioprotective effects in patients with cardiovascular disease. In the Treating to New Targets (TNT)…”
Get full text

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease by Faergeman, Ole, MD, DMSc, Holme, Ingar, PhD, Fayyad, Rana, PhD, Bhatia, Sonal, MD, Grundy, Scott M., MD, PhD, Kastelein, John J.P., MD, PhD, LaRosa, John C., MD, Larsen, Mogens Lytken, MD, DMSc, Lindahl, Christina, MD, Olsson, Anders G., MD, PhD, Tikkanen, Matti J., MD, PhD, Waters, David D., MD, Pedersen, Terje R., MD, PhD

“…We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease…”
Get full text

Safety and Efficacy of Atorvastatin -Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study) by LaRosa, John C., MD, Grundy, Scott M., MD, PhD, Kastelein, John J.P., MD, Kostis, John B., MD, Greten, Heiner, MD

“…High-dose statin therapy has been demonstrated to provide incremental benefit when low-density lipoprotein (LDL) cholesterol concentrations are lowered well…”
Get full text

Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means by LaRosa, John C., MD

“…Many epidemiologic studies and clinical trials have demonstrated the linear relation between elevated serum levels of low-density lipoprotein (LDL) cholesterol…”
Get full text

Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events by LaRosa, John C., MD, Pedersen, Terje R., MD, PhD, Somaratne, Ransi, MD, Wasserman, Scott M., MD

“…Based on the cardiovascular (CV) outcomes data derived predominantly from 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) trials, guidelines…”
Get full text

Living With Imprecision by LaRosa, John C., MD

“…[...]there are ratios of atherogenic to antiatherogenic particles, including LDL-C/HDL-C and apolipoprotein B/apolipoprotein A (the major apolipoprotein of…”
Get full text

Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial) by LaRosa, John C., MD, Deedwania, Prakash C., MD, Shepherd, James, MD, Wenger, Nanette K., MD, Greten, Heiner, MD, DeMicco, David A., PharmD, Breazna, Andrei, PhD

“…Analyses of randomized clinical trials are usually restricted to examination of time to first event. However, because many patients have multiple events, this…”
Get full text

How Much Statin Intervention Is Enough? by LaRosa, John C., MD

“…[...]a trial might address the interesting question of whether achievement of very low LDL levels would obviate the need to aggressively modify other risk…”
Get full text

Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery by Shah, Sanjiv J., MD, Waters, David D., MD, Barter, Philip, MD, Kastelein, John J.P., MD, PhD, Shepherd, James, MD, Wenger, Nanette K., MD, DeMicco, David A., DPharm, Breazna, Andrei, PhD, LaRosa, John C., MD

“…Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery Sanjiv J. Shah, David D. Waters, Philip…”
Get full text

Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study) by Johnson, Colleen, MD, Waters, David D., MD, DeMicco, David A., PharmD, Breazna, Andrei, PhD, Bittner, Vera, MD, Greten, Heiner, MD, Grundy, Scott M., MD, PhD, LaRosa, John C., MD

“…The Treating to New Targets (TNT) study demonstrated that intensive atorvastatin therapy to achieve low-density lipoprotein cholesterol concentrations well…”
Get full text

Means and Ends of Statins and Low-Density Lipoprotein Cholesterol Lowering by LaRosa, John C., MD, FACP

Get full text

Retraction notice to “Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease” [Am Heart J 2012;164:387-393] by Bittner, Vera, MD, MSPH, Wenger, Nanette K., MD, Waters, David D., MD, DeMicco, David A., PharmD, Messig, Michael, PhD, LaRosa, John C., MD

“…[...]the failure of vitamin D levels to predict events as reported in our 2012 AHJ paper was not surprising and provided no reason to question the integrity of…”
Get full text

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials by BOEKHOLDT, S. Matthijs, HOVINGH, G. Kees, KEECH, Antony C, COLQUHOUN, David, HITMAN, Graham A, BETTERIDGE, D. John, CLEARFIELD, Michael B, DOWNS, John R, COLHOUN, Helen M, GOTTO, Antonio M, RIDKER, Paul M, GRUNDY, Scott M, MORA, Samia, KASTELEIN, John J. P, ARSENAULT, Benoit J, AMARENCO, Pierre, PEDERSEN, Terje R, LAROSA, John C, WATERS, David D, DEMICCO, David A, SIMES, R. John

“…Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the consequence of this variability for cardiovascular disease risk is…”
Get full text

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis by Boekholdt, S. Matthijs, Arsenault, Benoit J, Mora, Samia, Pedersen, Terje R, LaRosa, John C, Nestel, Paul J, Simes, R. John, Durrington, Paul, Hitman, Graham A, Welch, K. M. A, DeMicco, David A, Zwinderman, Aeilko H, Clearfield, Michael B, Downs, John R, Tonkin, Andrew M, Colhoun, Helen M, Gotto, Antonio M, Ridker, Paul M, Kastelein, John J. P

“…CONTEXT The associations of low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB)…”
Get full text

RETRACTED: Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease [Am Heart J 2012;164:387-393] by Bittner, Vera, MD, MSPH, Wenger, Nanette K., MD, Waters, David D., MD, DeMicco, David A., PharmD, Messig, Michael, PhD, LaRosa, John C., MD

“…This article has been retracted: please see Elsevier Policy on Article Withdrawal ( http://www.elsevier.com/locate/withdrawalpolicy ). This article has been…”
Get full text

J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial by Bangalore, Sripal, Messerli, Franz H., Wun, Chuan-Chuan, Zuckerman, Andrea L., DeMicco, David, Kostis, John B., LaRosa, John C.

“…Aim In patients with coronary artery disease (CAD), a J-curve relationship has been reported between blood pressure (BP) and future cardiovascular events…”
Get full text

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events by Barter, Philip, Gotto, Antonio M, LaRosa, John C, Maroni, Jaman, Szarek, Michael, Grundy, Scott M, Kastelein, John J.P, Bittner, Vera, Fruchart, Jean-Charles

“…In a post hoc analysis of the Treating to New Targets study, high-density lipoprotein cholesterol levels in patients receiving statin therapy were shown to be…”
Get full text

Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis by Boekholdt, S. Matthijs, Arsenault, Benoit J., Hovingh, G. Kees, Mora, Samia, Pedersen, Terje R., LaRosa, John C., Welch, K.M.A., Amarenco, Pierre, DeMicco, David A., Tonkin, Andrew M., Sullivan, David R., Kirby, Adrienne, Colhoun, Helen M., Hitman, Graham A., Betteridge, D. John, Durrington, Paul N., Clearfield, Michael B., Downs, John R., Gotto, Antonio M., Ridker, Paul M., Kastelein, John J.P.

“…BACKGROUND—It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with…”
Get full text